DESCRIPTION OF PROJECT Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer KEYWORDS (MeSH terms only;minimum three) Prostate cancer, androgen receptor, RhoGDI, castration-resistance, proliferation BRIEF STATEMENT OF RESEARCH OBJECTIVES (Do not use continuation sheets) Treatment for disseminated prostate cancer (CaP) is the withdrawal of androgens. However, CaP eventually continues to grow in an androgen-independent or castration-resistant state. Great effort has focused on understanding the mechanisms involved in the development and progression of castration-resistant prostate cancer (CRPC). Androgen receptor (AR) appears to play a central role in the development and progression of CRPC. We have identified a novel signaling molecule namely RhoGDI1, using 2-D gel analysis of protein profile combined with protein sequencing, that is downregulated in prostate cancer and its downregulation plays critical role during prostate cancer progression to CRPC. The levels of RhoGDI1 expression were decreased in prostate cancer tissues compared to benign prostate tissues. Overexpression of RhoGDI1 inhibited the growth of castration-resistant prostate cancer cells and caused a reversal to an androgen-sensitive stage, while downregulation of RhoGDI1 enhanced androgen-sensitive prostate cancer cell growth in androgen-deprived conditions. Furthermore, RhoGDI1 suppressed AR expression and AR activation via interaction with AR. Based on these data, we hypothesize that loss of RhoGDI1 expression promotes the development and progression of prostate cancer by activating the AR signaling pathway. In this proposal, we will study the function of RhoGDI1 and elucidate the molecular pathways of RhoGDI1 interaction with androgen signaling during prostate cancer progression to castration-resistance.
The specific aims are: I. To examine the effects of RhoGDI1 on androgen responsiveness of prostate cancer cells in vitro We will knockdown RhoGDI1 expression in androgen-responsive LNCaP and LAPC-4 human prostate cancer cell lines, and overexpress RhoGDI1 in androgen-independent C4-2 and LNCaP-IL6+ cells to determine the effects of RhoGDI on cell growth and response to androgens. II. To examine the effects of RhoGDI1 on the development and progression of prostate cancer in vivo We will manipulate the levels of RhoGDI1 in prostate cancer cells and examine the effects of such manipulation on the formation and progression of tumors, as well as on the expression of androgen-inducible genes such as PSA in intact and castrated male athymic mice. III. To determine how RhoGDI1 interacts with AR signaling We will pinpoint the site of AR and RhoGDI1 interaction. We will examine if RhoGDI1 affects AR mRNA transcriptional initiation, protein turnover and nuclear translocation and DNA binding activity of AR. RhoGDI1 recruitment to the promoters of androgen responsive genes will be examined by chromatin immunoprecipitation (ChIP) assays. Potential impact on Veterans health care: Prostate cancer now exceeds lung cancer as the most commonly diagnosed cancer in the United States men, and it is the second leading cause of cancer death in that same population. A very large portion of men with prostate cancer are treated successfully with androgen deprivation therapy. However, virtually all patients will relapse due to acquisition of the growth of castration resistant tumor cells. Unfortunately, there is currently no effective treatment for men with castration resistant prostate cancer. The present proposal directly deals with the mechanisms of this evolution of castration resistant prostate cancer and has identified a critical factor involved in this process. Thus, this project targets castration resistant prostate cancer, a very significant health problem among male veterans. Our important mechanistic and pre-clinical studies will serve as the foundation for development of a mechanism based castration-adjunctive therapy, which may lead to a more effective intervention than castration alone. VA FORM 10-1313-2 Page 2 of VA Form 10-1313 package JUN 1990(R)

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX000526-04
Application #
8397517
Study Section
Oncology A (ONCA)
Project Start
2010-04-01
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2015-03-31
Support Year
4
Fiscal Year
2013
Total Cost
Indirect Cost
Name
VA Northern California Health Care System
Department
Type
DUNS #
127349889
City
Mather
State
CA
Country
United States
Zip Code
95655
Tummala, Ramakumar; Nadiminty, Nagalakshmi; Lou, Wei et al. (2016) Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate 76:445-55
Liu, Chengfei; Lou, Wei; Armstrong, Cameron et al. (2015) Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 75:1341-53
Nadiminty, Nagalakshmi; Tummala, Ramakumar; Liu, Chengfei et al. (2015) NF-?B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther 14:1884-95
Zhu, Yezi; Liu, Chengfei; Armstrong, Cameron et al. (2015) Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res 21:4133-42
Cui, Yuanyuan; Nadiminty, Nagalakshmi; Liu, Chengfei et al. (2014) Upregulation of glucose metabolism by NF-?B2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer 21:435-42
Liu, Chengfei; Zhu, Yezi; Lou, Wei et al. (2014) Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 74:201-9
Zhu, Yezi; Liu, Chengfei; Tummala, Ramakumar et al. (2013) RhoGDI? downregulates androgen receptor signaling in prostate cancer cells. Prostate 73:1614-22
Zhu, Yezi; Liu, Chengfei; Nadiminty, Nagalakshmi et al. (2013) Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 12:1829-36
Tummala, Ramakumar; Nadiminty, Nagalakshmi; Lou, Wei et al. (2013) Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 183:288-95
Liu, Chengfei; Zhu, Yezi; Lou, Wei et al. (2013) Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73:418-27

Showing the most recent 10 out of 13 publications